# Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV

> **NCT02124044** · PHASE2 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 30 (actual)

## Conditions studied

- HIV-HCV

## Interventions

- **DRUG:** Asunaprevir and Daclatasvir
- **DRUG:** Asunaprevir and Daclatasvir with BMS-791325

## Key facts

- **NCT ID:** NCT02124044
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-03
- **Final completion:** 2016-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-05-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02124044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02124044, "Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02124044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*